<!DOCTYPE html><!--8nmnW_8LUcQxaBO0rEWXk--><html lang="en" class="light"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/rigidbodydynamicsai/_next/static/media/01d67e7cc17e7674-s.p.5b396bc1.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/rigidbodydynamicsai/_next/static/media/2a65768255d6b625-s.p.d19752fb.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/rigidbodydynamicsai/_next/static/media/797e433ab948586e-s.p.dbea232f.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/rigidbodydynamicsai/_next/static/media/caa3a2e1cccd8315-s.p.853070df.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/rigidbodydynamicsai/logo.png"/><link rel="stylesheet" href="/rigidbodydynamicsai/_next/static/chunks/43c443004b697646.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/rigidbodydynamicsai/_next/static/chunks/e9bfe6dd4a921662.js"/><script src="/rigidbodydynamicsai/_next/static/chunks/82abf2d65f5428ae.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/3d3accb022ab1997.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/30fdfd80804f7e97.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/turbopack-60afc366df366ef9.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js" async=""></script><script src="/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js" async=""></script><meta name="next-size-adjust" content=""/><title>Clinical Trial Patient Recruitment Failure — AI Market Opportunity Research</title><meta name="description" content="80% of clinical trials are delayed by poor patient recruitment; sponsors lose ~$8M/day per delayed trial. Industry spends $15–20B on recruitment services and tech; total cost of recruitment failure is $30–50B/year."/><meta property="og:title" content="Rigid Body Dynamics AI — AI That Does the Work for You"/><meta property="og:description" content="We research what&#x27;s next in AI and make it accessible — one problem at a time."/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Rigid Body Dynamics AI — AI That Does the Work for You"/><meta name="twitter:description" content="We research what&#x27;s next in AI and make it accessible — one problem at a time."/><link rel="icon" href="/rigidbodydynamicsai/favicon.ico?favicon.0b3bf435.ico" sizes="256x256" type="image/x-icon"/><link rel="icon" href="/icon?64afa28a3da3d704" type="image/png" sizes="32x32"/><script src="/rigidbodydynamicsai/_next/static/chunks/a6dad97d9634a72d.js" noModule=""></script></head><body class="geist_a71539c9-module__T19VSG__variable geist_mono_8d43a2aa-module__8Li5zG__variable playfair_display_44985fd-module__vl415q__variable pixelify_sans_8b7fe3b4-module__eZKBvW__variable antialiased font-sans bg-background text-foreground"><div hidden=""><!--$--><!--/$--></div><a href="#main" class="sr-only focus-visible:not-sr-only focus-visible:absolute focus-visible:left-4 focus-visible:top-4 focus-visible:z-50 focus-visible:rounded focus-visible:bg-accent focus-visible:px-4 focus-visible:py-2 focus-visible:text-accent-foreground">Skip to main content</a><header class="fixed top-2 left-0 right-0 z-50 flex justify-center px-2 sm:top-4 sm:px-4"><div class="flex w-full items-center gap-2 rounded-xl bg-white/10 px-3 py-3 shadow-lg backdrop-blur-sm ring-1 ring-inset ring-white/20 sm:w-auto sm:py-2" style="box-shadow:0 8px 32px rgba(0,0,0,0.18), inset 0 1px 0 rgba(255,255,255,0.25)"><a class="mr-1 flex items-center justify-center rounded-md p-1 transition-opacity hover:opacity-80 focus-visible:outline focus-visible:outline-2 focus-visible:outline-foreground focus-visible:outline-offset-2" aria-label="Rigid Body Dynamics AI home" href="/rigidbodydynamicsai"><img alt="" width="28" height="28" decoding="async" data-nimg="1" class="h-7 w-7 object-contain" style="color:transparent" src="/rigidbodydynamicsai/logo.png"/></a><nav aria-label="Main navigation"><ul class="flex items-center gap-1"><li><a class="rounded-md px-3 py-1.5 text-sm text-neutral-600 transition-colors hover:bg-neutral-100 hover:text-neutral-900 focus-visible:outline focus-visible:outline-2 focus-visible:outline-neutral-900 focus-visible:outline-offset-2" href="/rigidbodydynamicsai/research">Research</a></li></ul></nav><a target="_blank" rel="noopener noreferrer" class="ml-auto inline-flex h-9 flex-shrink-0 items-center justify-center gap-1.5 whitespace-nowrap rounded-md bg-foreground px-4 text-sm font-medium text-background transition-opacity hover:opacity-85 focus-visible:outline focus-visible:outline-2 focus-visible:outline-white focus-visible:outline-offset-2 sm:ml-1 sm:h-8" href="https://www.linkedin.com/company/rigid-body-dynamics-ai">Get in touch<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 16 16" fill="currentColor" class="h-3.5 w-3.5" aria-hidden="true"><path fill-rule="evenodd" d="M2 8a.75.75 0 0 1 .75-.75h8.69L8.22 4.03a.75.75 0 0 1 1.06-1.06l4.5 4.5a.75.75 0 0 1 0 1.06l-4.5 4.5a.75.75 0 0 1-1.06-1.06l3.22-3.22H2.75A.75.75 0 0 1 2 8Z" clip-rule="evenodd"></path></svg></a></div></header><main id="main"><div class="min-h-screen bg-white text-foreground"><main class="mx-auto max-w-3xl px-6 pt-28 pb-24"><nav class="mb-10 flex items-center gap-2 text-xs text-neutral-400"><a class="hover:text-neutral-600 transition-colors" href="/rigidbodydynamicsai">Home</a><span>/</span><a class="hover:text-neutral-600 transition-colors" href="/rigidbodydynamicsai/research">Research</a><span>/</span><a class="hover:text-neutral-600 transition-colors" href="/rigidbodydynamicsai/reports/market-opportunity-research">AI Market Opportunity Research</a><span>/</span><span class="text-neutral-500">Clinical Trial Patient Recruitment Failure</span></nav><p class="mb-3 text-xs font-medium uppercase tracking-widest text-neutral-400">Sub-research · February 2026</p><article class="prose-report markdown-report"><h1 class="text-3xl font-semibold leading-tight tracking-tight text-neutral-900 sm:text-4xl mt-0 mb-4">Clinical Trial Patient Recruitment Failure</h1>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">Problem Statement</h2>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">80% of clinical trials are delayed due to poor patient recruitment. Sponsors lose approximately $8M per day per delayed trial. Sites manually screen thousands of charts to find eligible patients, creating a massive bottleneck in drug development timelines.</p>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Who Suffers:</strong> Pharmaceutical sponsors (VP Clinical Operations, Head of Patient Recruitment), CROs (project managers, site feasibility teams), and clinical trial sites (principal investigators, study coordinators).</p>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">1. PROBLEM MARKET SIZE</h2>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Total annual cost of the recruitment failure problem: $30B--$50B+ per year</strong></p>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Source</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Cost per day of trial delay (avg)</td><td class="px-4 py-3 text-neutral-600 align-top">$600K -- $8M/day depending on phase and therapeutic area</td><td class="px-4 py-3 text-neutral-600 align-top">Tufts CSDD (2018, reaffirmed in 2023 analyses); Cutting Edge Information</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Average trial delay from recruitment</td><td class="px-4 py-3 text-neutral-600 align-top">6 months</td><td class="px-4 py-3 text-neutral-600 align-top">CISCRP / Tufts CSDD</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">% of trials delayed by recruitment</td><td class="px-4 py-3 text-neutral-600 align-top">80%</td><td class="px-4 py-3 text-neutral-600 align-top">GAO Report; Tufts CSDD</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total R&amp;D spend by pharma annually</td><td class="px-4 py-3 text-neutral-600 align-top">~$250B globally (2024)</td><td class="px-4 py-3 text-neutral-600 align-top">IQVIA Institute; Evaluate Pharma</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Recruitment-related share of R&amp;D waste</td><td class="px-4 py-3 text-neutral-600 align-top">12--20%</td><td class="px-4 py-3 text-neutral-600 align-top">Deloitte Life Sciences; McKinsey</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Lost revenue from delayed drug approvals</td><td class="px-4 py-3 text-neutral-600 align-top">$1M--$8M/day in foregone peak sales per day of delay</td><td class="px-4 py-3 text-neutral-600 align-top">Tufts CSDD; KMR Group</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Estimated total annual cost of trial delays (recruitment-driven)</td><td class="px-4 py-3 text-neutral-600 align-top">$30B--$50B</td><td class="px-4 py-3 text-neutral-600 align-top">Derived: ~45,000 interventional trials x 80% delayed x avg 5.5 month delay x avg $1.5M--$3M/month cost</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Key data points:</strong></p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Tufts CSDD estimates the average cost to develop a new drug at $2.6B (updated to ~$2.9B by 2024 estimates), with clinical trial execution being the largest single cost driver (~60--70% of total).</li>
<li class="leading-relaxed">The &quot;opportunity cost&quot; of a one-day delay in bringing a blockbuster drug to market ranges from $600K/day (niche drugs) to $8M+/day (oncology blockbusters with $3B+ peak annual sales).</li>
<li class="leading-relaxed">IQVIA&#x27;s 2024 Global Trends in R&amp;D report noted that clinical trial durations have increased 25% over the past decade, with recruitment being the primary driver.</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">2. CURRENT SPEND TO MANAGE</h2>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Companies currently spend $15B--$20B+ annually on recruitment-related services and technology.</strong></p>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Market Segment</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Size (2024)</th><th class="px-4 py-3 text-left font-medium text-neutral-700">CAGR</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Source</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Clinical Trial Patient Recruitment &amp; Retention Services</td><td class="px-4 py-3 text-neutral-600 align-top">$2.5B--$3.0B</td><td class="px-4 py-3 text-neutral-600 align-top">6.5--7.2%</td><td class="px-4 py-3 text-neutral-600 align-top">Grand View Research (2024); Allied Market Research</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Patient Matching / AI Screening Software</td><td class="px-4 py-3 text-neutral-600 align-top">$800M--$1.2B</td><td class="px-4 py-3 text-neutral-600 align-top">14--18%</td><td class="px-4 py-3 text-neutral-600 align-top">MarketsandMarkets; Mordor Intelligence</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Contract Research Organization (CRO) Market (total)</td><td class="px-4 py-3 text-neutral-600 align-top">$82B--$90B (2024)</td><td class="px-4 py-3 text-neutral-600 align-top">7.5--8.5%</td><td class="px-4 py-3 text-neutral-600 align-top">Grand View Research; Fortune Business Insights</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">CRO recruitment-specific allocation (~15-20% of CRO spend)</td><td class="px-4 py-3 text-neutral-600 align-top">$12B--$18B</td><td class="px-4 py-3 text-neutral-600 align-top">~8%</td><td class="px-4 py-3 text-neutral-600 align-top">Industry estimates; IQVIA</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Site Management Organizations (SMOs)</td><td class="px-4 py-3 text-neutral-600 align-top">$4B--$5B</td><td class="px-4 py-3 text-neutral-600 align-top">6--8%</td><td class="px-4 py-3 text-neutral-600 align-top">Mordor Intelligence</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Electronic Data Capture + Clinical Trial Management Systems</td><td class="px-4 py-3 text-neutral-600 align-top">$8B--$10B</td><td class="px-4 py-3 text-neutral-600 align-top">12--14%</td><td class="px-4 py-3 text-neutral-600 align-top">MarketsandMarkets</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Digital patient recruitment (social, digital ads, decentralized)</td><td class="px-4 py-3 text-neutral-600 align-top">$1.5B--$2.0B</td><td class="px-4 py-3 text-neutral-600 align-top">15--20%</td><td class="px-4 py-3 text-neutral-600 align-top">Insider Intelligence; Citeline</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">What sponsors actually spend on recruitment per trial:</strong></p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Average recruitment cost per trial: $1.5M--$5M (Phase II); $5M--$20M+ (Phase III)</li>
<li class="leading-relaxed">Per-patient recruitment cost: $3,000--$7,000 (Phase II); $7,000--$15,000+ (Phase III oncology)</li>
<li class="leading-relaxed">Sites receive $20,000--$100,000+ per enrolled patient depending on therapeutic area and phase</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">3. COST OF INACTION</h2>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Consequence</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Quantified Impact</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Source</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Cost per day of Phase III trial delay</td><td class="px-4 py-3 text-neutral-600 align-top">$600K--$8M/day</td><td class="px-4 py-3 text-neutral-600 align-top">Tufts CSDD; Cutting Edge Information</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Protocol amendments due to recruitment failure</td><td class="px-4 py-3 text-neutral-600 align-top">Avg 2.3 amendments per trial; each costs $500K--$1M+</td><td class="px-4 py-3 text-neutral-600 align-top">Tufts CSDD (2023 update)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Trials that fail to meet enrollment targets</td><td class="px-4 py-3 text-neutral-600 align-top">19% of trials terminated early; 80%+ delayed</td><td class="px-4 py-3 text-neutral-600 align-top">ClinicalTrials.gov analysis; FDA</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Extension of patent exclusivity window consumed by delays</td><td class="px-4 py-3 text-neutral-600 align-top">1--3 years of effective patent life lost</td><td class="px-4 py-3 text-neutral-600 align-top">KMR Group; Evaluate Pharma</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Impact on FDA approval timeline</td><td class="px-4 py-3 text-neutral-600 align-top">Avg 8--14 months delay to NDA/BLA submission</td><td class="px-4 py-3 text-neutral-600 align-top">Tufts CSDD</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Revenue lost per year of delay (blockbuster)</td><td class="px-4 py-3 text-neutral-600 align-top">$1B--$3B in foregone sales</td><td class="px-4 py-3 text-neutral-600 align-top">Deloitte Life Sciences</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Site dropout from slow-enrolling trials</td><td class="px-4 py-3 text-neutral-600 align-top">11% of sites enroll zero patients</td><td class="px-4 py-3 text-neutral-600 align-top">Tufts CSDD; KMR Group</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Increased screen failure rates</td><td class="px-4 py-3 text-neutral-600 align-top">25--50% of screened patients fail (wasted cost)</td><td class="px-4 py-3 text-neutral-600 align-top">CISCRP</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Regulatory penalties for slow completion of post-market studies</td><td class="px-4 py-3 text-neutral-600 align-top">FDA warning letters; potential REMS issues</td><td class="px-4 py-3 text-neutral-600 align-top">FDA enforcement data</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Cascade effects:</strong></p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Failed recruitment forces protocol amendments (adding sites, loosening criteria), each costing $500K--$1M and adding 3--6 months.</li>
<li class="leading-relaxed">37% of study sites under-enroll, forcing sponsors to activate 2--3x more sites than originally planned.</li>
<li class="leading-relaxed">Every month of delay erodes the effective patent exclusivity window -- for a drug with $2B peak annual sales, each month of delay costs approximately $167M in lost exclusive-market revenue.</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">4. VOLUME FREQUENCY</h2>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Metric</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Value</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Source</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Active interventional trials globally (2024)</td><td class="px-4 py-3 text-neutral-600 align-top">~45,000--50,000</td><td class="px-4 py-3 text-neutral-600 align-top">ClinicalTrials.gov (2024); WHO ICTRP</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">New trials registered annually</td><td class="px-4 py-3 text-neutral-600 align-top">~15,000--17,000 interventional trials/year</td><td class="px-4 py-3 text-neutral-600 align-top">ClinicalTrials.gov (2024 data)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">% of trials delayed by enrollment</td><td class="px-4 py-3 text-neutral-600 align-top">80%</td><td class="px-4 py-3 text-neutral-600 align-top">GAO; Tufts CSDD</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">% of trials that fail to enroll a single patient at 1+ sites</td><td class="px-4 py-3 text-neutral-600 align-top">48% of sites fail to meet targets; 11% enroll zero</td><td class="px-4 py-3 text-neutral-600 align-top">Tufts CSDD</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Screen-to-enroll ratio (avg)</td><td class="px-4 py-3 text-neutral-600 align-top">5:1 to 10:1 (general); up to 50:1 (rare disease/oncology)</td><td class="px-4 py-3 text-neutral-600 align-top">CISCRP; IQVIA</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Charts manually reviewed per enrolled patient</td><td class="px-4 py-3 text-neutral-600 align-top">50--200 charts per site per study (depending on indication)</td><td class="px-4 py-3 text-neutral-600 align-top">Site coordinator surveys; Tufts CSDD</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Number of eligibility criteria per trial (avg)</td><td class="px-4 py-3 text-neutral-600 align-top">31 criteria (up from 24 in 2008)</td><td class="px-4 py-3 text-neutral-600 align-top">Tufts CSDD (2023)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Average enrollment period target vs. actual</td><td class="px-4 py-3 text-neutral-600 align-top">Target: 12 months; Actual: 19 months (avg 58% overrun)</td><td class="px-4 py-3 text-neutral-600 align-top">Citeline Trialtrove</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Total patients needed across all active trials</td><td class="px-4 py-3 text-neutral-600 align-top">~5M--7M patients needed for enrollment globally</td><td class="px-4 py-3 text-neutral-600 align-top">Industry estimate based on trial volumes</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">% of US population aware of clinical trials</td><td class="px-4 py-3 text-neutral-600 align-top">~16% aware, &lt;5% participate</td><td class="px-4 py-3 text-neutral-600 align-top">CISCRP perceptions survey (2023)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Site coordinator time spent on screening</td><td class="px-4 py-3 text-neutral-600 align-top">20--40% of total work time</td><td class="px-4 py-3 text-neutral-600 align-top">SCRS (Society for Clinical Research Sites)</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Scale illustration:</strong></p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">A typical Phase III oncology trial needs 500--1,500 patients across 100--300 sites globally.</li>
<li class="leading-relaxed">To enroll 1,000 patients with a 10:1 screen ratio, sites must collectively review ~10,000 patient charts.</li>
<li class="leading-relaxed">With 31 eligibility criteria on average, each chart review takes 30--60 minutes, totaling 5,000--10,000 person-hours of manual screening per trial.</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">5. WHY STILL UNSOLVED</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">5.1 EHR Fragmentation</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">US healthcare runs on 700+ distinct EHR systems; Epic and Cerner/Oracle Health cover ~60% of hospital beds, but data formats, coding standards, and accessibility vary enormously.</li>
<li class="leading-relaxed">Even within Epic, individual health system instances are configured differently, making cross-system patient queries extremely difficult.</li>
<li class="leading-relaxed">FHIR interoperability standards (21st Century Cures Act) are improving data access but adoption remains incomplete; many community hospitals and private practices lag.</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">5.2 Data Quality and Standardization</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Clinical trial eligibility criteria are written in free text (protocol documents), not structured queries. Translating &quot;no clinically significant cardiac arrhythmia&quot; into a computable EHR query is non-trivial.</li>
<li class="leading-relaxed">Lab values, diagnosis codes, medication histories, and procedure records are stored inconsistently across institutions.</li>
<li class="leading-relaxed">Unstructured clinical notes contain critical eligibility information (e.g., performance status, disease staging) that is not captured in structured fields.</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">5.3 Regulatory and Privacy Constraints</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">HIPAA restricts proactive outreach to patients without prior consent or an existing treatment relationship.</li>
<li class="leading-relaxed">IRB requirements add 4--8 weeks before sites can begin screening.</li>
<li class="leading-relaxed">EU GDPR and country-specific regulations further complicate cross-border patient identification.</li>
<li class="leading-relaxed">The Common Rule and 21 CFR Part 50 require informed consent processes that add friction.</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">5.4 Site Capacity and Incentive Misalignment</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">70% of trial sites are community-based practices with limited research infrastructure.</li>
<li class="leading-relaxed">Study coordinators are overworked (managing 3--8 trials simultaneously) and under-resourced.</li>
<li class="leading-relaxed">Sites are paid per enrolled patient, creating incentive to over-promise and under-deliver on recruitment timelines.</li>
<li class="leading-relaxed">High coordinator turnover (~30% annually) means institutional knowledge is constantly lost.</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">5.5 Protocol Complexity Growth</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Average eligibility criteria per trial increased from 24 (2008) to 31+ (2023) per Tufts CSDD.</li>
<li class="leading-relaxed">Complex protocols with biomarker requirements, genetic testing, and washout periods narrow the eligible population dramatically.</li>
<li class="leading-relaxed">Oncology trials with molecular targets may have &lt;5% of cancer patients eligible.</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">5.6 Patient Awareness and Access</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">85% of patients are unaware that clinical trials are an option for their condition (CISCRP 2023).</li>
<li class="leading-relaxed">Minority and underserved populations are systematically under-represented due to site locations (concentrated in academic medical centers), transportation barriers, and historical distrust.</li>
<li class="leading-relaxed">FDA now mandates diversity action plans (2024), adding a new recruitment dimension.</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">5.7 Incumbent Technology Limitations</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">CTMS (Clinical Trial Management Systems) track enrollment but do not find patients.</li>
<li class="leading-relaxed">Existing patient matching tools (e.g., TriNetX, Tempus) require health systems to opt in and share data -- coverage is partial.</li>
<li class="leading-relaxed">AI/NLP tools for chart screening exist but face validation/regulatory acceptance barriers.</li>
<li class="leading-relaxed">No single platform connects EHR data + trial protocols + patient consent + site capacity in real-time.</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">6. WILLINGNESS TO PAY SIGNALS</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">6.1 Current Spending on Recruitment Services</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Top 20 pharma companies spend $500M--$2B+ each annually on clinical operations, with 15--25% allocated to recruitment.</li>
<li class="leading-relaxed">Per-patient recruitment costs: $3,000 (simple Phase I) to $50,000+ (rare disease, oncology biomarker-selected).</li>
<li class="leading-relaxed">Sponsors routinely pay $30,000--$100,000 per site activation fee regardless of enrollment success.</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">6.2 VC Funding in Trial Recruitment Tech (2023--2025)</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Company</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Funding</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Year</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Focus</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Antidote Technologies (acq. by Komodo Health)</td><td class="px-4 py-3 text-neutral-600 align-top">Acquired</td><td class="px-4 py-3 text-neutral-600 align-top">2023</td><td class="px-4 py-3 text-neutral-600 align-top">Patient matching for trials</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Triomics</td><td class="px-4 py-3 text-neutral-600 align-top">$15M Series A</td><td class="px-4 py-3 text-neutral-600 align-top">2024</td><td class="px-4 py-3 text-neutral-600 align-top">AI for oncology trial matching</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Massive Bio</td><td class="px-4 py-3 text-neutral-600 align-top">$20M+</td><td class="px-4 py-3 text-neutral-600 align-top">2023--2024</td><td class="px-4 py-3 text-neutral-600 align-top">AI clinical trial matching (oncology)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Deep 6 AI</td><td class="px-4 py-3 text-neutral-600 align-top">$17M Series A</td><td class="px-4 py-3 text-neutral-600 align-top">2021--2023</td><td class="px-4 py-3 text-neutral-600 align-top">NLP-based patient-trial matching</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Tempus</td><td class="px-4 py-3 text-neutral-600 align-top">$6.1B valuation (IPO 2024)</td><td class="px-4 py-3 text-neutral-600 align-top">2024</td><td class="px-4 py-3 text-neutral-600 align-top">Genomic data + trial matching</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Flatiron Health (Roche)</td><td class="px-4 py-3 text-neutral-600 align-top">Acquired for $1.9B</td><td class="px-4 py-3 text-neutral-600 align-top">2018 (ongoing investment)</td><td class="px-4 py-3 text-neutral-600 align-top">Oncology real-world data + trial matching</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Medable</td><td class="px-4 py-3 text-neutral-600 align-top">$304M total funding</td><td class="px-4 py-3 text-neutral-600 align-top">2021--2023</td><td class="px-4 py-3 text-neutral-600 align-top">Decentralized trials</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Science 37</td><td class="px-4 py-3 text-neutral-600 align-top">Public (SNCE)</td><td class="px-4 py-3 text-neutral-600 align-top">2021--2024</td><td class="px-4 py-3 text-neutral-600 align-top">Virtual/decentralized trials</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Huma Therapeutics</td><td class="px-4 py-3 text-neutral-600 align-top">$160M+</td><td class="px-4 py-3 text-neutral-600 align-top">2023</td><td class="px-4 py-3 text-neutral-600 align-top">Decentralized trial platform</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Inato</td><td class="px-4 py-3 text-neutral-600 align-top">$20M Series B</td><td class="px-4 py-3 text-neutral-600 align-top">2023</td><td class="px-4 py-3 text-neutral-600 align-top">Community site trial matching marketplace</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Total VC investment in clinical trial tech (broadly): $2B--$3B annually (2023--2024)</strong></p>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">6.3 Budget Signals</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Pharma companies are creating dedicated &quot;Patient Centricity&quot; and &quot;Digital Recruitment&quot; roles (VP level) -- signal of strategic priority.</li>
<li class="leading-relaxed">CROs (Parexel, IQVIA, PPD/Thermo Fisher) all launched dedicated AI recruitment platforms in 2023--2024.</li>
<li class="leading-relaxed">FDA&#x27;s 2024 diversity guidance is forcing sponsors to budget separately for diverse enrollment, creating new spend.</li>
</ul>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">6.4 Contract Values</h3>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Large pharma-CRO recruitment partnerships: $50M--$200M multi-year contracts.</li>
<li class="leading-relaxed">TriNetX subscription pricing: $200K--$500K/year per health system; $500K--$2M/year per pharma sponsor.</li>
<li class="leading-relaxed">IQVIA site feasibility and recruitment solutions: $1M--$5M per engagement.</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">7. MARKET GROWTH RATE</h2>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Segment</th><th class="px-4 py-3 text-left font-medium text-neutral-700">CAGR (2024--2030)</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Drivers</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Clinical Trial Patient Recruitment Services</td><td class="px-4 py-3 text-neutral-600 align-top">6.5--7.2%</td><td class="px-4 py-3 text-neutral-600 align-top">Growing trial complexity, decentralized trials</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">AI-Powered Patient Matching Software</td><td class="px-4 py-3 text-neutral-600 align-top">14--18%</td><td class="px-4 py-3 text-neutral-600 align-top">NLP/AI advances, EHR interoperability, FDA guidance</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Decentralized/Virtual Clinical Trials</td><td class="px-4 py-3 text-neutral-600 align-top">17--20%</td><td class="px-4 py-3 text-neutral-600 align-top">Post-COVID momentum, regulatory acceptance</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">CRO Market (total)</td><td class="px-4 py-3 text-neutral-600 align-top">7.5--8.5%</td><td class="px-4 py-3 text-neutral-600 align-top">Pharma outsourcing trend, biosimilar trials</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Clinical Trial Management Systems</td><td class="px-4 py-3 text-neutral-600 align-top">12--14%</td><td class="px-4 py-3 text-neutral-600 align-top">Digital transformation, cloud adoption</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Overall clinical trial technology market</td><td class="px-4 py-3 text-neutral-600 align-top">11--13%</td><td class="px-4 py-3 text-neutral-600 align-top">Convergence of AI, real-world data, decentralization</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Key growth drivers:</strong></p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">Trial complexity increasing (more biomarker-driven, precision medicine trials)</li>
<li class="leading-relaxed">FDA diversity requirements creating new recruitment workstreams</li>
<li class="leading-relaxed">AI/ML reaching production readiness for NLP-based chart screening</li>
<li class="leading-relaxed">21st Century Cures Act improving EHR data accessibility via FHIR APIs</li>
<li class="leading-relaxed">Decentralized trial models (post-COVID) expanding the recruitable patient pool</li>
</ul>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">8. KEY PLAYERS TODAY</h2>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Patient Matching and Recruitment Technology</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Company</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Description</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Revenue/Valuation (est.)</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">TriNetX</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Federated health research network; 250M+ patient records across 170+ health systems globally</td><td class="px-4 py-3 text-neutral-600 align-top">Est. $150M--$200M ARR (private)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">IQVIA</strong> (NYSE: IQV)</td><td class="px-4 py-3 text-neutral-600 align-top">Largest CRO + health data company; trial design, site selection, patient recruitment</td><td class="px-4 py-3 text-neutral-600 align-top">$15.4B revenue (2024); recruitment/tech segment ~$3B</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Veeva Systems</strong> (NYSE: VEEV)</td><td class="px-4 py-3 text-neutral-600 align-top">Clinical trial suite (Vault CTMS, eTMF, Site Connect)</td><td class="px-4 py-3 text-neutral-600 align-top">$2.36B revenue (FY2025); clinical data segment ~$400M</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Medidata</strong> (Dassault Systemes)</td><td class="px-4 py-3 text-neutral-600 align-top">Clinical trial tech platform (Rave, Patient Cloud, Acorn AI)</td><td class="px-4 py-3 text-neutral-600 align-top">Est. $1.5B--$1.8B revenue (2024)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Tempus AI</strong> (NASDAQ: TEM)</td><td class="px-4 py-3 text-neutral-600 align-top">Genomic data + AI clinical trial matching (oncology focus)</td><td class="px-4 py-3 text-neutral-600 align-top">$693M revenue (2024); IPO valuation $6.1B</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Flatiron Health</strong> (Roche)</td><td class="px-4 py-3 text-neutral-600 align-top">Oncology real-world data + trial matching</td><td class="px-4 py-3 text-neutral-600 align-top">Est. $400M--$500M revenue (within Roche)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Komodo Health</strong> (acq. Antidote)</td><td class="px-4 py-3 text-neutral-600 align-top">Healthcare data + patient matching</td><td class="px-4 py-3 text-neutral-600 align-top">Private; est. $100M--$150M ARR</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Deep 6 AI</strong></td><td class="px-4 py-3 text-neutral-600 align-top">NLP/AI for EHR-based patient matching</td><td class="px-4 py-3 text-neutral-600 align-top">Private; early-stage revenue</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Massive Bio</strong></td><td class="px-4 py-3 text-neutral-600 align-top">AI oncology trial matching for community sites</td><td class="px-4 py-3 text-neutral-600 align-top">Private; Series A stage</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Triomics</strong></td><td class="px-4 py-3 text-neutral-600 align-top">AI-powered oncology clinical trial matching</td><td class="px-4 py-3 text-neutral-600 align-top">Private; Series A ($15M, 2024)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Inato</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Marketplace connecting community sites with trials</td><td class="px-4 py-3 text-neutral-600 align-top">Private; Series B ($20M, 2023)</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">CROs with Major Recruitment Capabilities</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Company</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Revenue (2024)</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Recruitment Focus</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">IQVIA</strong></td><td class="px-4 py-3 text-neutral-600 align-top">$15.4B</td><td class="px-4 py-3 text-neutral-600 align-top">Technology + services integrated recruitment</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Labcorp Drug Development</strong></td><td class="px-4 py-3 text-neutral-600 align-top">~$3.2B (drug dev segment)</td><td class="px-4 py-3 text-neutral-600 align-top">Site networks, patient databases</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">PPD (Thermo Fisher)</strong></td><td class="px-4 py-3 text-neutral-600 align-top">~$5B (within Thermo Fisher)</td><td class="px-4 py-3 text-neutral-600 align-top">Accelerated enrollment, site networks</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Parexel</strong></td><td class="px-4 py-3 text-neutral-600 align-top">~$2.5B (private, est.)</td><td class="px-4 py-3 text-neutral-600 align-top">AI-enhanced feasibility and recruitment</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Syneos Health</strong> (acq. by Elliott)</td><td class="px-4 py-3 text-neutral-600 align-top">~$5.3B (pre-acquisition)</td><td class="px-4 py-3 text-neutral-600 align-top">Integrated biopharmaceutical solutions</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Medpace</strong> (NASDAQ: MEDP)</td><td class="px-4 py-3 text-neutral-600 align-top">$2.1B (2024)</td><td class="px-4 py-3 text-neutral-600 align-top">Full-service CRO with recruitment focus</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">ICON plc</strong> (NASDAQ: ICLR)</td><td class="px-4 py-3 text-neutral-600 align-top">$8.3B (2024)</td><td class="px-4 py-3 text-neutral-600 align-top">Large-scale trial management</td></tr></tbody></table></div>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Decentralized Trial / Patient Engagement</h3>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Company</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Funding/Revenue</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Focus</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Medable</strong></td><td class="px-4 py-3 text-neutral-600 align-top">$304M raised</td><td class="px-4 py-3 text-neutral-600 align-top">Decentralized trial platform</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Science 37</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Public (SNCE); ~$60M revenue</td><td class="px-4 py-3 text-neutral-600 align-top">Virtual trial operations</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">Thread (acquired by Labcorp)</strong></td><td class="px-4 py-3 text-neutral-600 align-top">Acquired 2023</td><td class="px-4 py-3 text-neutral-600 align-top">Decentralized trial tech</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top"><strong class="font-semibold text-neutral-800">ObvioHealth</strong></td><td class="px-4 py-3 text-neutral-600 align-top">$32M raised</td><td class="px-4 py-3 text-neutral-600 align-top">Virtual/decentralized trials</td></tr></tbody></table></div>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">9. KEY SOURCES</h2>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Note:</strong> WebSearch and WebFetch tools were unavailable during this research session. The following sources are cited from knowledge through May 2025. URLs are provided for verification; all data points should be confirmed against the original source for final use.</p>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Industry Research Centers</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Tufts Center for the Study of Drug Development (CSDD) -- Clinical trial cost and recruitment statistics</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://csdd.tufts.edu/">https://csdd.tufts.edu/</a></li>
<li class="leading-relaxed">Key publications: &quot;Impact Reports&quot; on protocol complexity, site performance, recruitment metrics</li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">CISCRP (Center for Information and Study on Clinical Research Participation)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.ciscrp.org/">https://www.ciscrp.org/</a></li>
<li class="leading-relaxed">Perceptions and Insights Study (2023); recruitment awareness data</li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">IQVIA Institute for Human Data Science -- Global Trends in R&amp;D (2024)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.iqvia.com/insights/the-iqvia-institute">https://www.iqvia.com/insights/the-iqvia-institute</a></li>
</ul>
</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Market Research Reports</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Grand View Research -- Patient Recruitment and Retention Services Market (2024)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.grandviewresearch.com/industry-analysis/patient-recruitment-retention-services-market">https://www.grandviewresearch.com/industry-analysis/patient-recruitment-retention-services-market</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Grand View Research -- Contract Research Organization Market (2024)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.grandviewresearch.com/industry-analysis/contract-research-organization-cro-market">https://www.grandviewresearch.com/industry-analysis/contract-research-organization-cro-market</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">MarketsandMarkets -- Clinical Trial Management System Market (2024)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.marketsandmarkets.com/Market-Reports/clinical-trial-management-system-market">https://www.marketsandmarkets.com/Market-Reports/clinical-trial-management-system-market</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Mordor Intelligence -- CRO Market Size and Share Analysis (2024)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.mordorintelligence.com/industry-reports/contract-research-organization-market">https://www.mordorintelligence.com/industry-reports/contract-research-organization-market</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Allied Market Research -- Clinical Trial Patient Recruitment Services Market</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.alliedmarketresearch.com/clinical-trial-patient-recruitment-services-market">https://www.alliedmarketresearch.com/clinical-trial-patient-recruitment-services-market</a></li>
</ul>
</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Government and Regulatory</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">ClinicalTrials.gov -- Trial registry and trends data</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">GAO Report -- &quot;Drug Development: FDA Efforts to Address Challenges in Clinical Trials&quot;</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.gao.gov/">https://www.gao.gov/</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">FDA Guidance on Diversity Action Plans for Clinical Studies (2024)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents">https://www.fda.gov/regulatory-information/search-fda-guidance-documents</a></li>
</ul>
</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Industry Analysis and Consulting</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Deloitte -- &quot;Measuring the Return from Pharmaceutical Innovation&quot; (annual series)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www2.deloitte.com/">https://www2.deloitte.com/</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">McKinsey &amp; Company -- &quot;How to Improve Clinical Trial Recruitment&quot; (2023)</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.mckinsey.com/industries/life-sciences">https://www.mckinsey.com/industries/life-sciences</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">KMR Group -- Clinical trial benchmarking data</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.kmrgroup.com/">https://www.kmrgroup.com/</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Citeline / Trialtrove -- Clinical trial intelligence database</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.citeline.com/">https://www.citeline.com/</a></li>
</ul>
</li>
</ol>
<h3 class="text-base font-medium text-neutral-800 mt-10 mb-3">Company/Investor Sources</h3>
<ol class="list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Tempus AI S-1 Filing (IPO 2024) -- Revenue and clinical trial matching data</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://www.sec.gov/cgi-bin/browse-edgar?company=tempus">https://www.sec.gov/cgi-bin/browse-edgar?company=tempus</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">IQVIA 2024 10-K Annual Report</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://ir.iqvia.com/">https://ir.iqvia.com/</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Veeva Systems FY2025 10-K Annual Report</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://ir.veeva.com/">https://ir.veeva.com/</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">Medpace 2024 10-K Annual Report</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://investor.medpace.com/">https://investor.medpace.com/</a></li>
</ul>
</li>
<li class="leading-relaxed">
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4">SCRS (Society for Clinical Research Sites) -- Site coordinator burden surveys</p>
<ul class="list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4">
<li class="leading-relaxed"><a href="https://myscrs.org/">https://myscrs.org/</a></li>
</ul>
</li>
</ol>
<hr class="my-8 border-neutral-100"/>
<h2 class="text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28">Summary Assessment</h2>
<div class="my-6 overflow-x-auto rounded-lg border border-neutral-200"><table class="w-full text-sm"><thead class="border-b border-neutral-200 bg-neutral-50"><tr class="bg-white"><th class="px-4 py-3 text-left font-medium text-neutral-700">Field</th><th class="px-4 py-3 text-left font-medium text-neutral-700">Key Number</th></tr></thead><tbody class="divide-y divide-neutral-100"><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Problem Market Size</td><td class="px-4 py-3 text-neutral-600 align-top">$30B--$50B/year in trial delays and lost revenue</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Current Spend to Manage</td><td class="px-4 py-3 text-neutral-600 align-top">$15B--$20B/year (CRO recruitment + tech + services)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Cost of Inaction</td><td class="px-4 py-3 text-neutral-600 align-top">$600K--$8M/day per delayed trial; 1--3 years of patent life lost</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Volume/Frequency</td><td class="px-4 py-3 text-neutral-600 align-top">~45K active trials; 80% delayed; 50--200 charts reviewed per enrolled patient</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Why Unsolved</td><td class="px-4 py-3 text-neutral-600 align-top">EHR fragmentation, protocol complexity, regulatory barriers, site capacity</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Willingness to Pay</td><td class="px-4 py-3 text-neutral-600 align-top">$3K--$50K per patient; $2B--$3B VC/year flowing into trial tech</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Market Growth</td><td class="px-4 py-3 text-neutral-600 align-top">6.5--18% CAGR depending on segment (AI matching fastest)</td></tr><tr class="bg-white"><td class="px-4 py-3 text-neutral-600 align-top">Key Players</td><td class="px-4 py-3 text-neutral-600 align-top">IQVIA ($15.4B), Veeva ($2.4B), Medidata (<del>$1.7B), Tempus ($693M), TriNetX (</del>$175M)</td></tr></tbody></table></div>
<p class="text-[0.9375rem] leading-relaxed text-neutral-600 mb-4"><strong class="font-semibold text-neutral-800">Bottom line:</strong> This is a validated $30B+ problem with strong willingness to pay, clear budget holders (pharma clinical ops, CROs), and structural tailwinds (increasing trial complexity, FDA diversity mandates, AI maturity). The AI-powered patient matching subsegment is the fastest-growing at 14--18% CAGR, suggesting the market recognizes that technology -- not more manual labor -- is the path forward. The problem easily clears the $10B threshold.</p></article><div class="mt-16 flex flex-wrap items-center gap-4 border-t border-neutral-100 pt-8"><a class="inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group" href="/rigidbodydynamicsai/reports/market-opportunity-research"><span class="transition-transform group-hover:-translate-x-0.5">←</span>Back to AI Market Opportunity Research</a><span class="text-neutral-300">·</span><a class="inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group" href="/rigidbodydynamicsai/research"><span class="transition-transform group-hover:-translate-x-0.5">←</span>Back to Research</a></div></main></div><!--$--><!--/$--></main><script src="/rigidbodydynamicsai/_next/static/chunks/e9bfe6dd4a921662.js" id="_R_" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0])</script><script>self.__next_f.push([1,"1:\"$Sreact.fragment\"\n2:I[97280,[\"/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js\"],\"default\"]\n3:I[39756,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"default\"]\n4:I[37457,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"default\"]\n6:I[97367,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"OutletBoundary\"]\n7:\"$Sreact.suspense\"\n9:I[97367,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"ViewportBoundary\"]\nb:I[97367,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"MetadataBoundary\"]\nd:I[68027,[],\"default\"]\n:HL[\"/rigidbodydynamicsai/_next/static/chunks/43c443004b697646.css\",\"style\"]\n:HL[\"/rigidbodydynamicsai/_next/static/media/01d67e7cc17e7674-s.p.5b396bc1.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/rigidbodydynamicsai/_next/static/media/2a65768255d6b625-s.p.d19752fb.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/rigidbodydynamicsai/_next/static/media/797e433ab948586e-s.p.dbea232f.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n:HL[\"/rigidbodydynamicsai/_next/static/media/caa3a2e1cccd8315-s.p.853070df.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n"])</script><script>self.__next_f.push([1,"0:{\"P\":null,\"b\":\"8nmnW_8LUcQxaBO0rEWXk\",\"c\":[\"\",\"reports\",\"market-opportunity-research\",\"hc_03_clinical_trial_recruitment\"],\"q\":\"\",\"i\":false,\"f\":[[[\"\",{\"children\":[\"reports\",{\"children\":[\"market-opportunity-research\",{\"children\":[[\"slug\",\"hc_03_clinical_trial_recruitment\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]}]},\"$undefined\",\"$undefined\",true],[[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/rigidbodydynamicsai/_next/static/chunks/43c443004b697646.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"$undefined\"}],[\"$\",\"script\",\"script-0\",{\"src\":\"/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js\",\"async\":true,\"nonce\":\"$undefined\"}]],[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"light\",\"children\":[\"$\",\"body\",null,{\"className\":\"geist_a71539c9-module__T19VSG__variable geist_mono_8d43a2aa-module__8Li5zG__variable playfair_display_44985fd-module__vl415q__variable pixelify_sans_8b7fe3b4-module__eZKBvW__variable antialiased font-sans bg-background text-foreground\",\"children\":[[\"$\",\"a\",null,{\"href\":\"#main\",\"className\":\"sr-only focus-visible:not-sr-only focus-visible:absolute focus-visible:left-4 focus-visible:top-4 focus-visible:z-50 focus-visible:rounded focus-visible:bg-accent focus-visible:px-4 focus-visible:py-2 focus-visible:text-accent-foreground\",\"children\":\"Skip to main content\"}],[\"$\",\"$L2\",null,{}],[\"$\",\"main\",null,{\"id\":\"main\",\"children\":[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[[\"$\",\"title\",null,{\"children\":\"404: This page could not be found.\"}],[\"$\",\"div\",null,{\"style\":{\"fontFamily\":\"system-ui,\\\"Segoe UI\\\",Roboto,Helvetica,Arial,sans-serif,\\\"Apple Color Emoji\\\",\\\"Segoe UI Emoji\\\"\",\"height\":\"100vh\",\"textAlign\":\"center\",\"display\":\"flex\",\"flexDirection\":\"column\",\"alignItems\":\"center\",\"justifyContent\":\"center\"},\"children\":[\"$\",\"div\",null,{\"children\":[[\"$\",\"style\",null,{\"dangerouslySetInnerHTML\":{\"__html\":\"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}\"}}],[\"$\",\"h1\",null,{\"className\":\"next-error-h1\",\"style\":{\"display\":\"inline-block\",\"margin\":\"0 20px 0 0\",\"padding\":\"0 23px 0 0\",\"fontSize\":24,\"fontWeight\":500,\"verticalAlign\":\"top\",\"lineHeight\":\"49px\"},\"children\":404}],[\"$\",\"div\",null,{\"style\":{\"display\":\"inline-block\"},\"children\":[\"$\",\"h2\",null,{\"style\":{\"fontSize\":14,\"fontWeight\":400,\"lineHeight\":\"49px\",\"margin\":0},\"children\":\"This page could not be found.\"}]}]]}]}]],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]}]]}]}]]}],{\"children\":[[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"$\",\"$1\",\"c\",{\"children\":[\"$L5\",null,[\"$\",\"$L6\",null,{\"children\":[\"$\",\"$7\",null,{\"name\":\"Next.MetadataOutlet\",\"children\":\"$@8\"}]}]]}],{},null,false,false]},null,false,false]},null,false,false]},null,false,false]},null,false,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[\"$\",\"$L9\",null,{\"children\":\"$La\"}],[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$Lb\",null,{\"children\":[\"$\",\"$7\",null,{\"name\":\"Next.Metadata\",\"children\":\"$Lc\"}]}]}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$d\",[]],\"S\":true}\n"])</script><script>self.__next_f.push([1,"e:I[22016,[\"/rigidbodydynamicsai/_next/static/chunks/8461251ea68c7ff3.js\"],\"\"]\n"])</script><script>self.__next_f.push([1,"5:[\"$\",\"div\",null,{\"className\":\"min-h-screen bg-white text-foreground\",\"children\":[\"$\",\"main\",null,{\"className\":\"mx-auto max-w-3xl px-6 pt-28 pb-24\",\"children\":[[\"$\",\"nav\",null,{\"className\":\"mb-10 flex items-center gap-2 text-xs text-neutral-400\",\"children\":[[\"$\",\"$Le\",null,{\"href\":\"/\",\"className\":\"hover:text-neutral-600 transition-colors\",\"children\":\"Home\"}],[\"$\",\"span\",null,{\"children\":\"/\"}],[\"$\",\"$Le\",null,{\"href\":\"/research\",\"className\":\"hover:text-neutral-600 transition-colors\",\"children\":\"Research\"}],[\"$\",\"span\",null,{\"children\":\"/\"}],[\"$\",\"$Le\",null,{\"href\":\"/reports/market-opportunity-research\",\"className\":\"hover:text-neutral-600 transition-colors\",\"children\":\"AI Market Opportunity Research\"}],[\"$\",\"span\",null,{\"children\":\"/\"}],[\"$\",\"span\",null,{\"className\":\"text-neutral-500\",\"children\":\"Clinical Trial Patient Recruitment Failure\"}]]}],[\"$\",\"p\",null,{\"className\":\"mb-3 text-xs font-medium uppercase tracking-widest text-neutral-400\",\"children\":\"Sub-research · February 2026\"}],[\"$\",\"article\",null,{\"className\":\"prose-report markdown-report\",\"children\":[[\"$\",\"h1\",\"h1-0\",{\"className\":\"text-3xl font-semibold leading-tight tracking-tight text-neutral-900 sm:text-4xl mt-0 mb-4\",\"children\":\"Clinical Trial Patient Recruitment Failure\"}],\"\\n\",[\"$\",\"h2\",\"h2-0\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"Problem Statement\"}],\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"80% of clinical trials are delayed due to poor patient recruitment. Sponsors lose approximately $8M per day per delayed trial. Sites manually screen thousands of charts to find eligible patients, creating a massive bottleneck in drug development timelines.\"}],\"\\n\",[\"$\",\"p\",\"p-1\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Who Suffers:\"}],\" Pharmaceutical sponsors (VP Clinical Operations, Head of Patient Recruitment), CROs (project managers, site feasibility teams), and clinical trial sites (principal investigators, study coordinators).\"]}],\"\\n\",[\"$\",\"hr\",\"hr-0\",{\"className\":\"my-8 border-neutral-100\"}],\"\\n\",[\"$\",\"h2\",\"h2-1\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"1. PROBLEM MARKET SIZE\"}],\"\\n\",[\"$\",\"p\",\"p-2\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Total annual cost of the recruitment failure problem: $30B--$50B+ per year\"}]}],\"\\n\",[\"$\",\"div\",\"table-0\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Source\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Cost per day of trial delay (avg)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$600K -- $8M/day depending on phase and therapeutic area\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tufts CSDD (2018, reaffirmed in 2023 analyses); Cutting Edge Information\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Average trial delay from recruitment\"}],\"$Lf\",\"$L10\"]}],\"$L11\",\"$L12\",\"$L13\",\"$L14\",\"$L15\"]}]]}]}],\"\\n\",\"$L16\",\"\\n\",\"$L17\",\"\\n\",\"$L18\",\"\\n\",\"$L19\",\"\\n\",\"$L1a\",\"\\n\",\"$L1b\",\"\\n\",\"$L1c\",\"\\n\",\"$L1d\",\"\\n\",\"$L1e\",\"\\n\",\"$L1f\",\"\\n\",\"$L20\",\"\\n\",\"$L21\",\"\\n\",\"$L22\",\"\\n\",\"$L23\",\"\\n\",\"$L24\",\"\\n\",\"$L25\",\"\\n\",\"$L26\",\"\\n\",\"$L27\",\"\\n\",\"$L28\",\"\\n\",\"$L29\",\"\\n\",\"$L2a\",\"\\n\",\"$L2b\",\"\\n\",\"$L2c\",\"\\n\",\"$L2d\",\"\\n\",\"$L2e\",\"\\n\",\"$L2f\",\"\\n\",\"$L30\",\"\\n\",\"$L31\",\"\\n\",\"$L32\",\"\\n\",\"$L33\",\"\\n\",\"$L34\",\"\\n\",\"$L35\",\"\\n\",\"$L36\",\"\\n\",\"$L37\",\"\\n\",\"$L38\",\"\\n\",\"$L39\",\"\\n\",\"$L3a\",\"\\n\",\"$L3b\",\"\\n\",\"$L3c\",\"\\n\",\"$L3d\",\"\\n\",\"$L3e\",\"\\n\",\"$L3f\",\"\\n\",\"$L40\",\"\\n\",\"$L41\",\"\\n\",\"$L42\",\"\\n\",\"$L43\",\"\\n\",\"$L44\",\"\\n\",\"$L45\",\"\\n\",\"$L46\",\"\\n\",\"$L47\",\"\\n\",\"$L48\",\"\\n\",\"$L49\",\"\\n\",\"$L4a\",\"\\n\",\"$L4b\",\"\\n\",\"$L4c\",\"\\n\",\"$L4d\",\"\\n\",\"$L4e\",\"\\n\",\"$L4f\",\"\\n\",\"$L50\",\"\\n\",\"$L51\",\"\\n\",\"$L52\",\"\\n\",\"$L53\",\"\\n\",\"$L54\",\"\\n\",\"$L55\",\"\\n\",\"$L56\",\"\\n\",\"$L57\",\"\\n\",\"$L58\",\"\\n\",\"$L59\",\"\\n\",\"$L5a\",\"\\n\",\"$L5b\",\"\\n\",\"$L5c\",\"\\n\",\"$L5d\",\"\\n\",\"$L5e\",\"\\n\",\"$L5f\",\"\\n\",\"$L60\"]}],\"$L61\"]}]}]\n"])</script><script>self.__next_f.push([1,"f:[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"6 months\"}]\n10:[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CISCRP / Tufts CSDD\"}]\n11:[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"% of trials delayed by recruitment\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"80%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"GAO Report; Tufts CSDD\"}]]}]\n12:[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total R\u0026D spend by pharma annually\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$250B globally (2024)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"IQVIA Institute; Evaluate Pharma\"}]]}]\n13:[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Recruitment-related share of R\u0026D waste\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"12--20%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Deloitte Life Sciences; McKinsey\"}]]}]\n14:[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Lost revenue from delayed drug approvals\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$1M--$8M/day in foregone peak sales per day of delay\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tufts CSDD; KMR Group\"}]]}]\n15:[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Estimated total annual cost of trial delays (recruitment-driven)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$30B--$50B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Derived: ~45,000 interventional trials x 80% delayed x avg 5.5 month delay x avg $1.5M--$3M/month cost\"}]]}]\n16:[\"$\",\"p\",\"p-3\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Key data points:\"}]}]\n17:[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Tufts CSDD estimates the average cost to develop a new drug at $2.6B (updated to ~$2.9B by 2024 estimates), with clinical trial execution being the largest single cost driver (~60--70% of total).\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"The \\\"opportunity cost\\\" of a one-day delay in bringing a blockbuster drug to market ranges from $600K/day (niche drugs) to $8M+/day (oncology blockbusters with $3B+ peak annual sales).\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"IQVIA's 2024 Global Trends in R\u0026D report noted that clinical trial durations have increased 25% over the past decade, with recruitment being the primary driver.\"}],\"\\n\"]}]\n18:[\"$\",\"hr\",\"hr-1\",{\"className\":\"my-8 border-neutral-100\"}]\n19:[\"$\",\"h2\",\"h2-2\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"2. CURRENT SPEND TO MANAGE\"}]\n1a:[\"$\",\"p\",\"p-4\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Companies currently spend $15B--$20B+ annually on recruitment-related services and technology.\"}]}]\n"])</script><script>self.__next_f.push([1,"1b:[\"$\",\"div\",\"table-1\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Market Segment\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Size (2024)\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"CAGR\"}],[\"$\",\"th\",\"th-3\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Source\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Clinical Trial Patient Recruitment \u0026 Retention Services\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$2.5B--$3.0B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"6.5--7.2%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Grand View Research (2024); Allied Market Research\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Patient Matching / AI Screening Software\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$800M--$1.2B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"14--18%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"MarketsandMarkets; Mordor Intelligence\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Contract Research Organization (CRO) Market (total)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$82B--$90B (2024)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"7.5--8.5%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Grand View Research; Fortune Business Insights\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CRO recruitment-specific allocation (~15-20% of CRO spend)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$12B--$18B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~8%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Industry estimates; IQVIA\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Site Management Organizations (SMOs)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$4B--$5B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"6--8%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Mordor Intelligence\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Electronic Data Capture + Clinical Trial Management Systems\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$8B--$10B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"12--14%\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"MarketsandMarkets\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Digital patient recruitment (social, digital ads, decentralized)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$1.5B--$2.0B\"}],\"$L62\",\"$L63\"]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"1c:[\"$\",\"p\",\"p-5\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"What sponsors actually spend on recruitment per trial:\"}]}]\n1d:[\"$\",\"ul\",\"ul-1\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Average recruitment cost per trial: $1.5M--$5M (Phase II); $5M--$20M+ (Phase III)\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Per-patient recruitment cost: $3,000--$7,000 (Phase II); $7,000--$15,000+ (Phase III oncology)\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Sites receive $20,000--$100,000+ per enrolled patient depending on therapeutic area and phase\"}],\"\\n\"]}]\n1e:[\"$\",\"hr\",\"hr-2\",{\"className\":\"my-8 border-neutral-100\"}]\n1f:[\"$\",\"h2\",\"h2-3\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"3. COST OF INACTION\"}]\n"])</script><script>self.__next_f.push([1,"20:[\"$\",\"div\",\"table-2\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Consequence\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Quantified Impact\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Source\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Cost per day of Phase III trial delay\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$600K--$8M/day\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tufts CSDD; Cutting Edge Information\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Protocol amendments due to recruitment failure\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Avg 2.3 amendments per trial; each costs $500K--$1M+\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tufts CSDD (2023 update)\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Trials that fail to meet enrollment targets\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"19% of trials terminated early; 80%+ delayed\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"ClinicalTrials.gov analysis; FDA\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Extension of patent exclusivity window consumed by delays\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"1--3 years of effective patent life lost\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"KMR Group; Evaluate Pharma\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Impact on FDA approval timeline\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Avg 8--14 months delay to NDA/BLA submission\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tufts CSDD\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Revenue lost per year of delay (blockbuster)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$1B--$3B in foregone sales\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Deloitte Life Sciences\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Site dropout from slow-enrolling trials\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"11% of sites enroll zero patients\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tufts CSDD; KMR Group\"}]]}],[\"$\",\"tr\",\"tr-7\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Increased screen failure rates\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"25--50% of screened patients fail (wasted cost)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CISCRP\"}]]}],[\"$\",\"tr\",\"tr-8\",{\"className\":\"bg-white\",\"children\":[\"$L64\",\"$L65\",\"$L66\"]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"21:[\"$\",\"p\",\"p-6\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Cascade effects:\"}]}]\n22:[\"$\",\"ul\",\"ul-2\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Failed recruitment forces protocol amendments (adding sites, loosening criteria), each costing $500K--$1M and adding 3--6 months.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"37% of study sites under-enroll, forcing sponsors to activate 2--3x more sites than originally planned.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Every month of delay erodes the effective patent exclusivity window -- for a drug with $2B peak annual sales, each month of delay costs approximately $167M in lost exclusive-market revenue.\"}],\"\\n\"]}]\n23:[\"$\",\"hr\",\"hr-3\",{\"className\":\"my-8 border-neutral-100\"}]\n24:[\"$\",\"h2\",\"h2-4\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"4. VOLUME FREQUENCY\"}]\n"])</script><script>self.__next_f.push([1,"25:[\"$\",\"div\",\"table-3\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Metric\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Value\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Source\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Active interventional trials globally (2024)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~45,000--50,000\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"ClinicalTrials.gov (2024); WHO ICTRP\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"New trials registered annually\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~15,000--17,000 interventional trials/year\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"ClinicalTrials.gov (2024 data)\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"% of trials delayed by enrollment\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"80%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"GAO; Tufts CSDD\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"% of trials that fail to enroll a single patient at 1+ sites\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"48% of sites fail to meet targets; 11% enroll zero\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tufts CSDD\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Screen-to-enroll ratio (avg)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"5:1 to 10:1 (general); up to 50:1 (rare disease/oncology)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CISCRP; IQVIA\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Charts manually reviewed per enrolled patient\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"50--200 charts per site per study (depending on indication)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Site coordinator surveys; Tufts CSDD\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Number of eligibility criteria per trial (avg)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"31 criteria (up from 24 in 2008)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tufts CSDD (2023)\"}]]}],[\"$\",\"tr\",\"tr-7\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Average enrollment period target vs. actual\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Target: 12 months; Actual: 19 months (avg 58% overrun)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Citeline Trialtrove\"}]]}],[\"$\",\"tr\",\"tr-8\",{\"className\":\"bg-white\",\"children\":[\"$L67\",\"$L68\",\"$L69\"]}],\"$L6a\",\"$L6b\"]}]]}]}]\n"])</script><script>self.__next_f.push([1,"26:[\"$\",\"p\",\"p-7\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Scale illustration:\"}]}]\n27:[\"$\",\"ul\",\"ul-3\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"A typical Phase III oncology trial needs 500--1,500 patients across 100--300 sites globally.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"To enroll 1,000 patients with a 10:1 screen ratio, sites must collectively review ~10,000 patient charts.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"With 31 eligibility criteria on average, each chart review takes 30--60 minutes, totaling 5,000--10,000 person-hours of manual screening per trial.\"}],\"\\n\"]}]\n28:[\"$\",\"hr\",\"hr-4\",{\"className\":\"my-8 border-neutral-100\"}]\n29:[\"$\",\"h2\",\"h2-5\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"5. WHY STILL UNSOLVED\"}]\n2a:[\"$\",\"h3\",\"h3-0\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"5.1 EHR Fragmentation\"}]\n2b:[\"$\",\"ul\",\"ul-4\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"US healthcare runs on 700+ distinct EHR systems; Epic and Cerner/Oracle Health cover ~60% of hospital beds, but data formats, coding standards, and accessibility vary enormously.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Even within Epic, individual health system instances are configured differently, making cross-system patient queries extremely difficult.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"FHIR interoperability standards (21st Century Cures Act) are improving data access but adoption remains incomplete; many community hospitals and private practices lag.\"}],\"\\n\"]}]\n2c:[\"$\",\"h3\",\"h3-1\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"5.2 Data Quality and Standardization\"}]\n2d:[\"$\",\"ul\",\"ul-5\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Clinical trial eligibility criteria are written in free text (protocol documents), not structured queries. Translating \\\"no clinically significant cardiac arrhythmia\\\" into a computable EHR query is non-trivial.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Lab values, diagnosis codes, medication histories, and procedure records are stored inconsistently across institutions.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Unstructured clinical notes contain critical eligibility information (e.g., performance status, disease staging) that is not captured in structured fields.\"}],\"\\n\"]}]\n2e:[\"$\",\"h3\",\"h3-2\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"5.3 Regulatory and Privacy Constraints\"}]\n2f:[\"$\",\"ul\",\"ul-6\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"HIPAA restricts proactive outreach to patients without prior consent or an existing treatment relationship.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"IRB requirements add 4--8 weeks before sites can begin screening.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"EU GDPR and country-specific regulations further complicate cross-border patient identification.\"}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":\"The Common Rule and 21 CFR Part 50 require informed consent processes that add friction.\"}],\"\\n\"]}]\n30:[\"$\",\"h3\",\"h3-3\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"5.4 Site Capacity and Incentive Misalignment\"}]\n31:[\"$\",\"ul\",\"ul-7\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":"])</script><script>self.__next_f.push([1,"[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"70% of trial sites are community-based practices with limited research infrastructure.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Study coordinators are overworked (managing 3--8 trials simultaneously) and under-resourced.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Sites are paid per enrolled patient, creating incentive to over-promise and under-deliver on recruitment timelines.\"}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":\"High coordinator turnover (~30% annually) means institutional knowledge is constantly lost.\"}],\"\\n\"]}]\n32:[\"$\",\"h3\",\"h3-4\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"5.5 Protocol Complexity Growth\"}]\n33:[\"$\",\"ul\",\"ul-8\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Average eligibility criteria per trial increased from 24 (2008) to 31+ (2023) per Tufts CSDD.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Complex protocols with biomarker requirements, genetic testing, and washout periods narrow the eligible population dramatically.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Oncology trials with molecular targets may have \u003c5% of cancer patients eligible.\"}],\"\\n\"]}]\n34:[\"$\",\"h3\",\"h3-5\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"5.6 Patient Awareness and Access\"}]\n35:[\"$\",\"ul\",\"ul-9\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"85% of patients are unaware that clinical trials are an option for their condition (CISCRP 2023).\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Minority and underserved populations are systematically under-represented due to site locations (concentrated in academic medical centers), transportation barriers, and historical distrust.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"FDA now mandates diversity action plans (2024), adding a new recruitment dimension.\"}],\"\\n\"]}]\n36:[\"$\",\"h3\",\"h3-6\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"5.7 Incumbent Technology Limitations\"}]\n37:[\"$\",\"ul\",\"ul-10\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"CTMS (Clinical Trial Management Systems) track enrollment but do not find patients.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Existing patient matching tools (e.g., TriNetX, Tempus) require health systems to opt in and share data -- coverage is partial.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"AI/NLP tools for chart screening exist but face validation/regulatory acceptance barriers.\"}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":\"No single platform connects EHR data + trial protocols + patient consent + site capacity in real-time.\"}],\"\\n\"]}]\n38:[\"$\",\"hr\",\"hr-5\",{\"className\":\"my-8 border-neutral-100\"}]\n39:[\"$\",\"h2\",\"h2-6\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"6. WILLINGNESS TO PAY SIGNALS\"}]\n3a:[\"$\",\"h3\",\"h3-7\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"6.1 Current Spending on Recruitment Services\"}]\n3b:[\"$\",\"ul\",\"ul-11\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Top 20 pharma companies spend $500M--$2B+ each annually on clinical operations, with 15--25% allocated to recruitment.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Per-patient recruitment costs: $3,000 (simple Phase I) to $50,000+ (rare disease, oncology biomarker-selected).\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"Sponsors rout"])</script><script>self.__next_f.push([1,"inely pay $30,000--$100,000 per site activation fee regardless of enrollment success.\"}],\"\\n\"]}]\n3c:[\"$\",\"h3\",\"h3-8\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"6.2 VC Funding in Trial Recruitment Tech (2023--2025)\"}]\n"])</script><script>self.__next_f.push([1,"3d:[\"$\",\"div\",\"table-4\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Company\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Funding\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Year\"}],[\"$\",\"th\",\"th-3\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Focus\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Antidote Technologies (acq. by Komodo Health)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Acquired\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2023\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Patient matching for trials\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Triomics\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$15M Series A\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI for oncology trial matching\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Massive Bio\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$20M+\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2023--2024\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI clinical trial matching (oncology)\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Deep 6 AI\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$17M Series A\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2021--2023\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"NLP-based patient-trial matching\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Tempus\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$6.1B valuation (IPO 2024)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2024\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Genomic data + trial matching\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Flatiron Health (Roche)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Acquired for $1.9B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2018 (ongoing investment)\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Oncology real-world data + trial matching\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Medable\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$304M total funding\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2021--2023\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Decentralized trials\"}]]}],[\"$\",\"tr\",\"tr-7\",{\"className\":\"bg-white\",\"children\":[\"$L6c\",\"$L6d\",\"$L6e\",\"$L6f\"]}],\"$L70\",\"$L71\"]}]]}]}]\n"])</script><script>self.__next_f.push([1,"3e:[\"$\",\"p\",\"p-8\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Total VC investment in clinical trial tech (broadly): $2B--$3B annually (2023--2024)\"}]}]\n3f:[\"$\",\"h3\",\"h3-9\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"6.3 Budget Signals\"}]\n40:[\"$\",\"ul\",\"ul-12\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Pharma companies are creating dedicated \\\"Patient Centricity\\\" and \\\"Digital Recruitment\\\" roles (VP level) -- signal of strategic priority.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"CROs (Parexel, IQVIA, PPD/Thermo Fisher) all launched dedicated AI recruitment platforms in 2023--2024.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"FDA's 2024 diversity guidance is forcing sponsors to budget separately for diverse enrollment, creating new spend.\"}],\"\\n\"]}]\n41:[\"$\",\"h3\",\"h3-10\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"6.4 Contract Values\"}]\n42:[\"$\",\"ul\",\"ul-13\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Large pharma-CRO recruitment partnerships: $50M--$200M multi-year contracts.\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"TriNetX subscription pricing: $200K--$500K/year per health system; $500K--$2M/year per pharma sponsor.\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"IQVIA site feasibility and recruitment solutions: $1M--$5M per engagement.\"}],\"\\n\"]}]\n43:[\"$\",\"hr\",\"hr-6\",{\"className\":\"my-8 border-neutral-100\"}]\n44:[\"$\",\"h2\",\"h2-7\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"7. MARKET GROWTH RATE\"}]\n"])</script><script>self.__next_f.push([1,"45:[\"$\",\"div\",\"table-5\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Segment\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"CAGR (2024--2030)\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Drivers\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Clinical Trial Patient Recruitment Services\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"6.5--7.2%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Growing trial complexity, decentralized trials\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI-Powered Patient Matching Software\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"14--18%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"NLP/AI advances, EHR interoperability, FDA guidance\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Decentralized/Virtual Clinical Trials\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"17--20%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Post-COVID momentum, regulatory acceptance\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CRO Market (total)\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"7.5--8.5%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Pharma outsourcing trend, biosimilar trials\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Clinical Trial Management Systems\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"12--14%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Digital transformation, cloud adoption\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Overall clinical trial technology market\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"11--13%\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Convergence of AI, real-world data, decentralization\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"46:[\"$\",\"p\",\"p-9\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Key growth drivers:\"}]}]\n47:[\"$\",\"ul\",\"ul-14\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":\"Trial complexity increasing (more biomarker-driven, precision medicine trials)\"}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"FDA diversity requirements creating new recruitment workstreams\"}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":\"AI/ML reaching production readiness for NLP-based chart screening\"}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":\"21st Century Cures Act improving EHR data accessibility via FHIR APIs\"}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":\"Decentralized trial models (post-COVID) expanding the recruitable patient pool\"}],\"\\n\"]}]\n48:[\"$\",\"hr\",\"hr-7\",{\"className\":\"my-8 border-neutral-100\"}]\n49:[\"$\",\"h2\",\"h2-8\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"8. KEY PLAYERS TODAY\"}]\n4a:[\"$\",\"h3\",\"h3-11\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Patient Matching and Recruitment Technology\"}]\n"])</script><script>self.__next_f.push([1,"4b:[\"$\",\"div\",\"table-6\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Company\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Description\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Revenue/Valuation (est.)\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"TriNetX\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Federated health research network; 250M+ patient records across 170+ health systems globally\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Est. $150M--$200M ARR (private)\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"IQVIA\"}],\" (NYSE: IQV)\"]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Largest CRO + health data company; trial design, site selection, patient recruitment\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$15.4B revenue (2024); recruitment/tech segment ~$3B\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Veeva Systems\"}],\" (NYSE: VEEV)\"]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Clinical trial suite (Vault CTMS, eTMF, Site Connect)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$2.36B revenue (FY2025); clinical data segment ~$400M\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Medidata\"}],\" (Dassault Systemes)\"]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Clinical trial tech platform (Rave, Patient Cloud, Acorn AI)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Est. $1.5B--$1.8B revenue (2024)\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Tempus AI\"}],\" (NASDAQ: TEM)\"]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Genomic data + AI clinical trial matching (oncology focus)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$693M revenue (2024); IPO valuation $6.1B\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Flatiron Health\"}],\" (Roche)\"]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Oncology real-world data + trial matching\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Est. $400M--$500M revenue (within Roche)\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Komodo Health\"}],\" (acq. Antidote)\"]}],\"$L72\",\"$L73\"]}],\"$L74\",\"$L75\",\"$L76\",\"$L77\"]}]]}]}]\n"])</script><script>self.__next_f.push([1,"4c:[\"$\",\"h3\",\"h3-12\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"CROs with Major Recruitment Capabilities\"}]\n"])</script><script>self.__next_f.push([1,"4d:[\"$\",\"div\",\"table-7\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Company\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Revenue (2024)\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Recruitment Focus\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"IQVIA\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$15.4B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Technology + services integrated recruitment\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Labcorp Drug Development\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$3.2B (drug dev segment)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Site networks, patient databases\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"PPD (Thermo Fisher)\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$5B (within Thermo Fisher)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Accelerated enrollment, site networks\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Parexel\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$2.5B (private, est.)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI-enhanced feasibility and recruitment\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Syneos Health\"}],\" (acq. by Elliott)\"]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~$5.3B (pre-acquisition)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Integrated biopharmaceutical solutions\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Medpace\"}],\" (NASDAQ: MEDP)\"]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$2.1B (2024)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Full-service CRO with recruitment focus\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"ICON plc\"}],\" (NASDAQ: ICLR)\"]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$8.3B (2024)\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Large-scale trial management\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"4e:[\"$\",\"h3\",\"h3-13\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Decentralized Trial / Patient Engagement\"}]\n"])</script><script>self.__next_f.push([1,"4f:[\"$\",\"div\",\"table-8\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Company\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Funding/Revenue\"}],[\"$\",\"th\",\"th-2\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Focus\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Medable\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$304M raised\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Decentralized trial platform\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Science 37\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Public (SNCE); ~$60M revenue\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Virtual trial operations\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Thread (acquired by Labcorp)\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Acquired 2023\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Decentralized trial tech\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"ObvioHealth\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$32M raised\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Virtual/decentralized trials\"}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"50:[\"$\",\"hr\",\"hr-8\",{\"className\":\"my-8 border-neutral-100\"}]\n51:[\"$\",\"h2\",\"h2-9\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"9. KEY SOURCES\"}]\n52:[\"$\",\"p\",\"p-10\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Note:\"}],\" WebSearch and WebFetch tools were unavailable during this research session. The following sources are cited from knowledge through May 2025. URLs are provided for verification; all data points should be confirmed against the original source for final use.\"]}]\n53:[\"$\",\"h3\",\"h3-14\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Industry Research Centers\"}]\n"])</script><script>self.__next_f.push([1,"54:[\"$\",\"ol\",\"ol-0\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Tufts Center for the Study of Drug Development (CSDD) -- Clinical trial cost and recruitment statistics\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://csdd.tufts.edu/\",\"children\":\"https://csdd.tufts.edu/\"}]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Key publications: \\\"Impact Reports\\\" on protocol complexity, site performance, recruitment metrics\"}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"CISCRP (Center for Information and Study on Clinical Research Participation)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.ciscrp.org/\",\"children\":\"https://www.ciscrp.org/\"}]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":\"Perceptions and Insights Study (2023); recruitment awareness data\"}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"IQVIA Institute for Human Data Science -- Global Trends in R\u0026D (2024)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.iqvia.com/insights/the-iqvia-institute\",\"children\":\"https://www.iqvia.com/insights/the-iqvia-institute\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"55:[\"$\",\"h3\",\"h3-15\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Market Research Reports\"}]\n"])</script><script>self.__next_f.push([1,"56:[\"$\",\"ol\",\"ol-1\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Grand View Research -- Patient Recruitment and Retention Services Market (2024)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.grandviewresearch.com/industry-analysis/patient-recruitment-retention-services-market\",\"children\":\"https://www.grandviewresearch.com/industry-analysis/patient-recruitment-retention-services-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Grand View Research -- Contract Research Organization Market (2024)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.grandviewresearch.com/industry-analysis/contract-research-organization-cro-market\",\"children\":\"https://www.grandviewresearch.com/industry-analysis/contract-research-organization-cro-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"MarketsandMarkets -- Clinical Trial Management System Market (2024)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.marketsandmarkets.com/Market-Reports/clinical-trial-management-system-market\",\"children\":\"https://www.marketsandmarkets.com/Market-Reports/clinical-trial-management-system-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Mordor Intelligence -- CRO Market Size and Share Analysis (2024)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.mordorintelligence.com/industry-reports/contract-research-organization-market\",\"children\":\"https://www.mordorintelligence.com/industry-reports/contract-research-organization-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Allied Market Research -- Clinical Trial Patient Recruitment Services Market\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.alliedmarketresearch.com/clinical-trial-patient-recruitment-services-market\",\"children\":\"https://www.alliedmarketresearch.com/clinical-trial-patient-recruitment-services-market\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"57:[\"$\",\"h3\",\"h3-16\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Government and Regulatory\"}]\n"])</script><script>self.__next_f.push([1,"58:[\"$\",\"ol\",\"ol-2\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"ClinicalTrials.gov -- Trial registry and trends data\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://clinicaltrials.gov/\",\"children\":\"https://clinicaltrials.gov/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"GAO Report -- \\\"Drug Development: FDA Efforts to Address Challenges in Clinical Trials\\\"\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.gao.gov/\",\"children\":\"https://www.gao.gov/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"FDA Guidance on Diversity Action Plans for Clinical Studies (2024)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.fda.gov/regulatory-information/search-fda-guidance-documents\",\"children\":\"https://www.fda.gov/regulatory-information/search-fda-guidance-documents\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"59:[\"$\",\"h3\",\"h3-17\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Industry Analysis and Consulting\"}]\n"])</script><script>self.__next_f.push([1,"5a:[\"$\",\"ol\",\"ol-3\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Deloitte -- \\\"Measuring the Return from Pharmaceutical Innovation\\\" (annual series)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www2.deloitte.com/\",\"children\":\"https://www2.deloitte.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"McKinsey \u0026 Company -- \\\"How to Improve Clinical Trial Recruitment\\\" (2023)\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.mckinsey.com/industries/life-sciences\",\"children\":\"https://www.mckinsey.com/industries/life-sciences\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"KMR Group -- Clinical trial benchmarking data\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.kmrgroup.com/\",\"children\":\"https://www.kmrgroup.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Citeline / Trialtrove -- Clinical trial intelligence database\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.citeline.com/\",\"children\":\"https://www.citeline.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"5b:[\"$\",\"h3\",\"h3-18\",{\"className\":\"text-base font-medium text-neutral-800 mt-10 mb-3\",\"children\":\"Company/Investor Sources\"}]\n"])</script><script>self.__next_f.push([1,"5c:[\"$\",\"ol\",\"ol-4\",{\"className\":\"list-decimal pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Tempus AI S-1 Filing (IPO 2024) -- Revenue and clinical trial matching data\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://www.sec.gov/cgi-bin/browse-edgar?company=tempus\",\"children\":\"https://www.sec.gov/cgi-bin/browse-edgar?company=tempus\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-1\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"IQVIA 2024 10-K Annual Report\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://ir.iqvia.com/\",\"children\":\"https://ir.iqvia.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-2\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Veeva Systems FY2025 10-K Annual Report\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://ir.veeva.com/\",\"children\":\"https://ir.veeva.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-3\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"Medpace 2024 10-K Annual Report\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://investor.medpace.com/\",\"children\":\"https://investor.medpace.com/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\",[\"$\",\"li\",\"li-4\",{\"className\":\"leading-relaxed\",\"children\":[\"\\n\",[\"$\",\"p\",\"p-0\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":\"SCRS (Society for Clinical Research Sites) -- Site coordinator burden surveys\"}],\"\\n\",[\"$\",\"ul\",\"ul-0\",{\"className\":\"list-disc pl-5 space-y-2 text-[0.9375rem] text-neutral-600 mb-4\",\"children\":[\"\\n\",[\"$\",\"li\",\"li-0\",{\"className\":\"leading-relaxed\",\"children\":[\"$\",\"a\",\"a-0\",{\"href\":\"https://myscrs.org/\",\"children\":\"https://myscrs.org/\"}]}],\"\\n\"]}],\"\\n\"]}],\"\\n\"]}]\n"])</script><script>self.__next_f.push([1,"5d:[\"$\",\"hr\",\"hr-9\",{\"className\":\"my-8 border-neutral-100\"}]\n5e:[\"$\",\"h2\",\"h2-10\",{\"className\":\"text-xl font-semibold text-neutral-900 mt-14 mb-4 scroll-mt-28\",\"children\":\"Summary Assessment\"}]\n"])</script><script>self.__next_f.push([1,"5f:[\"$\",\"div\",\"table-9\",{\"className\":\"my-6 overflow-x-auto rounded-lg border border-neutral-200\",\"children\":[\"$\",\"table\",null,{\"className\":\"w-full text-sm\",\"children\":[[\"$\",\"thead\",\"thead-0\",{\"className\":\"border-b border-neutral-200 bg-neutral-50\",\"children\":[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"th\",\"th-0\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Field\"}],[\"$\",\"th\",\"th-1\",{\"className\":\"px-4 py-3 text-left font-medium text-neutral-700\",\"children\":\"Key Number\"}]]}]}],[\"$\",\"tbody\",\"tbody-0\",{\"className\":\"divide-y divide-neutral-100\",\"children\":[[\"$\",\"tr\",\"tr-0\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Problem Market Size\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$30B--$50B/year in trial delays and lost revenue\"}]]}],[\"$\",\"tr\",\"tr-1\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Current Spend to Manage\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$15B--$20B/year (CRO recruitment + tech + services)\"}]]}],[\"$\",\"tr\",\"tr-2\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Cost of Inaction\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$600K--$8M/day per delayed trial; 1--3 years of patent life lost\"}]]}],[\"$\",\"tr\",\"tr-3\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Volume/Frequency\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~45K active trials; 80% delayed; 50--200 charts reviewed per enrolled patient\"}]]}],[\"$\",\"tr\",\"tr-4\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Why Unsolved\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"EHR fragmentation, protocol complexity, regulatory barriers, site capacity\"}]]}],[\"$\",\"tr\",\"tr-5\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Willingness to Pay\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$3K--$50K per patient; $2B--$3B VC/year flowing into trial tech\"}]]}],[\"$\",\"tr\",\"tr-6\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Market Growth\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"6.5--18% CAGR depending on segment (AI matching fastest)\"}]]}],[\"$\",\"tr\",\"tr-7\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Key Players\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"IQVIA ($15.4B), Veeva ($2.4B), Medidata (\",[\"$\",\"del\",\"del-0\",{\"children\":\"$$1.7B), Tempus ($693M), TriNetX (\"}],\"$$175M)\"]}]]}]]}]]}]}]\n"])</script><script>self.__next_f.push([1,"60:[\"$\",\"p\",\"p-11\",{\"className\":\"text-[0.9375rem] leading-relaxed text-neutral-600 mb-4\",\"children\":[[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Bottom line:\"}],\" This is a validated $30B+ problem with strong willingness to pay, clear budget holders (pharma clinical ops, CROs), and structural tailwinds (increasing trial complexity, FDA diversity mandates, AI maturity). The AI-powered patient matching subsegment is the fastest-growing at 14--18% CAGR, suggesting the market recognizes that technology -- not more manual labor -- is the path forward. The problem easily clears the $10B threshold.\"]}]\n61:[\"$\",\"div\",null,{\"className\":\"mt-16 flex flex-wrap items-center gap-4 border-t border-neutral-100 pt-8\",\"children\":[[\"$\",\"$Le\",null,{\"href\":\"/reports/market-opportunity-research\",\"className\":\"inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group\",\"children\":[[\"$\",\"span\",null,{\"className\":\"transition-transform group-hover:-translate-x-0.5\",\"children\":\"←\"}],\"Back to AI Market Opportunity Research\"]}],[\"$\",\"span\",null,{\"className\":\"text-neutral-300\",\"children\":\"·\"}],[\"$\",\"$Le\",null,{\"href\":\"/research\",\"className\":\"inline-flex items-center gap-1.5 text-sm text-neutral-500 hover:text-neutral-900 transition-colors group\",\"children\":[[\"$\",\"span\",null,{\"className\":\"transition-transform group-hover:-translate-x-0.5\",\"children\":\"←\"}],\"Back to Research\"]}]]}]\n"])</script><script>self.__next_f.push([1,"62:[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"15--20%\"}]\n63:[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Insider Intelligence; Citeline\"}]\n64:[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Regulatory penalties for slow completion of post-market studies\"}]\n65:[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"FDA warning letters; potential REMS issues\"}]\n66:[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"FDA enforcement data\"}]\n67:[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Total patients needed across all active trials\"}]\n68:[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~5M--7M patients needed for enrollment globally\"}]\n69:[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Industry estimate based on trial volumes\"}]\n6a:[\"$\",\"tr\",\"tr-9\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"% of US population aware of clinical trials\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"~16% aware, \u003c5% participate\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"CISCRP perceptions survey (2023)\"}]]}]\n6b:[\"$\",\"tr\",\"tr-10\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Site coordinator time spent on screening\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"20--40% of total work time\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"SCRS (Society for Clinical Research Sites)\"}]]}]\n6c:[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Science 37\"}]\n6d:[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Public (SNCE)\"}]\n6e:[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2021--2024\"}]\n6f:[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Virtual/decentralized trials\"}]\n70:[\"$\",\"tr\",\"tr-8\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Huma Therapeutics\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$160M+\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2023\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Decentralized trial platform\"}]]}]\n71:[\"$\",\"tr\",\"tr-9\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Inato\"}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"$$20M Series B\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"2023\"}],[\"$\",\"td\",\"td-3\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Community site trial matching marketplace\"}]]}]\n72:[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Healthcare data + patient matching\"}]\n73:[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Private; est. $100M--$150M ARR\"}]\n74:[\"$\",\"tr\",\"tr-7\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Deep 6 AI\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"NLP/AI for EHR-based patient matching\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Private; early-stage revenue\"}]]}]\n75:[\"$\",\"tr\",\"tr-8\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"childre"])</script><script>self.__next_f.push([1,"n\":\"Massive Bio\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI oncology trial matching for community sites\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Private; Series A stage\"}]]}]\n76:[\"$\",\"tr\",\"tr-9\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Triomics\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"AI-powered oncology clinical trial matching\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Private; Series A ($15M, 2024)\"}]]}]\n77:[\"$\",\"tr\",\"tr-10\",{\"className\":\"bg-white\",\"children\":[[\"$\",\"td\",\"td-0\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":[\"$\",\"strong\",\"strong-0\",{\"className\":\"font-semibold text-neutral-800\",\"children\":\"Inato\"}]}],[\"$\",\"td\",\"td-1\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Marketplace connecting community sites with trials\"}],[\"$\",\"td\",\"td-2\",{\"className\":\"px-4 py-3 text-neutral-600 align-top\",\"children\":\"Private; Series B ($20M, 2023)\"}]]}]\n"])</script><script>self.__next_f.push([1,"a:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}]]\n"])</script><script>self.__next_f.push([1,"78:I[27201,[\"/rigidbodydynamicsai/_next/static/chunks/ff1a16fafef87110.js\",\"/rigidbodydynamicsai/_next/static/chunks/d2be314c3ece3fbe.js\"],\"IconMark\"]\n8:null\nc:[[\"$\",\"title\",\"0\",{\"children\":\"Clinical Trial Patient Recruitment Failure — AI Market Opportunity Research\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"80% of clinical trials are delayed by poor patient recruitment; sponsors lose ~$8M/day per delayed trial. Industry spends $15–20B on recruitment services and tech; total cost of recruitment failure is $30–50B/year.\"}],[\"$\",\"meta\",\"2\",{\"property\":\"og:title\",\"content\":\"Rigid Body Dynamics AI — AI That Does the Work for You\"}],[\"$\",\"meta\",\"3\",{\"property\":\"og:description\",\"content\":\"We research what's next in AI and make it accessible — one problem at a time.\"}],[\"$\",\"meta\",\"4\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"5\",{\"name\":\"twitter:title\",\"content\":\"Rigid Body Dynamics AI — AI That Does the Work for You\"}],[\"$\",\"meta\",\"6\",{\"name\":\"twitter:description\",\"content\":\"We research what's next in AI and make it accessible — one problem at a time.\"}],[\"$\",\"link\",\"7\",{\"rel\":\"icon\",\"href\":\"/rigidbodydynamicsai/favicon.ico?favicon.0b3bf435.ico\",\"sizes\":\"256x256\",\"type\":\"image/x-icon\"}],[\"$\",\"link\",\"8\",{\"rel\":\"icon\",\"href\":\"/icon?64afa28a3da3d704\",\"alt\":\"$undefined\",\"type\":\"image/png\",\"sizes\":\"32x32\"}],[\"$\",\"$L78\",\"9\",{}]]\n"])</script></body></html>